The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (4) , 885-892
Abstract
Background: Afatinib is a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been approved by the Food and Drug Administration for the treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. We performed a meta-analysis to assess the efficacy and safety of afatinib in advanced NSCLC.Keywords
This publication has 28 references indexed in Scilit:
- Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patientsExperimental and Therapeutic Medicine, 2014
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Clinical perspective of afatinib in non-small cell lung cancerLung Cancer, 2013
- Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family BlockerThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialThe Lancet Oncology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Update onEpidermal Growth Factor ReceptorMutations in Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998